Steady Expansion Forecast for Oral Proteins And Peptides Market, Projected to Reach $3.49 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Oral Proteins And Peptides Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for oral proteins and peptides has seen an accelerated growth recently. It is projected to expand from $1.27 billion in 2024 to $1.56 billion in 2025, with a compound annual growth rate (CAGR) of 22.7%. This historical growth can be traced back to the increasing incidence of chronic conditions, escalating investments in biotechnology for creating oral protein-based therapies, a heightened consumer inclination towards non-invasive treatments, burgeoning biopharmaceutical sector, and an augmenting emphasis on personalized medicine.

Oral Proteins And Peptides Market Size Forecast: What's the Projected Valuation by 2029?
The market for oral proteins and peptides is projected to experience significant expansion in the coming years, swelling to $3.49 billion by 2029 with a compound annual growth rate (CAGR) of 22.3%. The predicted growth in this forecast period is due to an increased emphasis on patient-oriented medications, a growing elderly population, higher healthcare spending, an escalating requirement for cancer diagnostics, and an elevated preference for orally administered drugs. Key trends in this forecast period encompass the creation of new oral peptides offering improved stability and effectiveness, the incorporation of artificial intelligence for discovering oral formulations, advanced medical procedures, progress in drug delivery technologies, and inventive oral insulin formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

What Are the Drivers Transforming the Oral Proteins And Peptides Market?
The escalation of the biopharmaceutical sector is set to significantly drive the expansion of the oral proteins and peptides market. This subsector of the larger pharmaceutical industry is devoted to the creation, production, and market introduction of biological source-based medicines. The upward trend of this sector can be attributed to biotechnology advancements, an increasing demand for personalized medication, widespread chronic diseases, and elevated investment in research and development. Oral proteins and peptides in this industry offers the potential for non-invasive therapeutic delivery, improving patient adherence to medication and decreasing the necessity for injections. They are capable of targeting specific diseases with superior stability and increased absorption in the digestive system. The European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based European trade association representing the pharmaceutical industry, reported for instance, that total biopharmaceutical production in Europe in June 2023 was $384,200 million (€340,000 million), a roughly 4.95% rise from $366,267 million (€323,950 million) in 2021. The growth of the biopharmaceutical industry is thus contributing significantly to the burgeoning oral proteins and peptides market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Long-Term Trends Will Define the Future of the Oral Proteins And Peptides Market?
Significant players in the oral proteins and peptides market, such as Oral Semaglutide, are centering their efforts on creating groundbreaking products to improve comfort and patient adherence. The innovation of oral semaglutide has greatly contributed to the development of oral proteins and peptides. This medication, a glucagon-like peptide-1 (GLP-1) receptor agonist, is typically prescribed by injection for type 2 diabetes and recently for obesity. For example, the first-ever oral semaglutide was launched by Novo Nordisk India, a healthcare company based in India, in January 2022, signifying a fantastic leap forward in treatment for diabetes. Semaglutide was previously only available in an injectable form, but now an oral form is available for those managing type 2 diabetes, providing an easier alternative. This significant progress not only evolves the approach to diabetes treatment but also paves the way for future advancements in oral insulin formulas, potentially offering more efficient and friendly treatment options for patients.

Which Segments in the Oral Proteins And Peptides Market Offer the Most Profit Potential?
The oral proteins and peptidesmarket covered in this report is segmented -

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Which Firms Dominate the Oral Proteins And Peptides Market by Market Share and Revenue in 2025?
Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Which Regions Offer the Highest Growth Potential in the Oral Proteins And Peptides Market?
North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19629

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.